FDA Cancer Drug Meeting Could Provide Insight into Agency's Rx/Dx Position | GenomeWeb
NEW YORK (GenomeWeb News) - The US Food and Drug Administration’s Oncologic Drugs Advisory Committee will meet Tuesday in Gaithersburg, Md., to discuss the validity of conducting retrospective clinical trials to define the genetic subpopulation for two metastatic colorectal cancer drugs, Amgen’s Vectibix and ImClone/Bristol-Myers Squibb Erbitux. 
 
The meeting could result in the FDA providing further clarity to pharmacogenomics companies on the agency’s position regarding Rx/Dx co-development.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.